In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
Medical Device Research and Development Strategies

In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC

Executive Summary

Why would imaging giant Siemens buy traditional in vitro diagnostics firm Diagnostic Products for $1.86 billion? Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables, look attractive. But more than that, it's becoming apparent that on the molecular level, in vivo imaging and in vitro diagnostics are converging.
Table

View full table

Advertisement

Related Content

Medtech Insight
The Digital Pathology Revolution: Breaking the Glass Ceiling
In Vivo
Trends for the New Year: Can Medtech Build on the Success of 2007?
Medtech Insight
Acquisitions in 2007: Medical Device Companies Regroup
In Vivo
Siemens--Stealing GE's Thunder
In Vivo
Does Roche Have It Right?
In Vivo
GE Grabs the Spotlight in IVD
Medtech Insight
Claros Diagnostics Inc.
In Vivo
Headlines Obscure Robust Year for Devices in 2006
In Vivo
Siemens acquires Bayer Diagnostics, Creates Integrated Diagnostics Powerhouse
In Vivo
Deal Statistics Quarterly, Q2 2006

Topics

Related Companies

Related Deals

Advertisement
Tags:
Medical Device Research and Development Strategies
UsernamePublicRestriction

Register

IV002762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By